Our story

The spark for establishing Cerenion came when Dr. Jukka Kortelainen, MD PhD, one of the co-founders of the company, was completing his residency at the Department of Clinical Neurophysiology at the Oulu University Hospital.
While working in the Intensive Care Unit (ICU), Jukka realized just how little was known about the brain function of the patients treated at the ICU. The function of the heart and the lungs was monitored carefully, but little attention was often given to the brain even though it is perhaps the most vital of organs. This despite the fact that inadequate monitoring of brain function may significantly impair the treatment of the patient and increase the costs of care. This is what Cerenion set out to change.
Today, Cerenion has a portfolio of international patents, a growing body of clinical evidence from multisite studies and 16 employees at 2 locations in Finland. Our main office is located at the heart of the internationally recognized Oulu Health ecosystem in Oulu and our satellite office is located in the capital region.
You can meet us at either location, or at one of the many international conferences and trade fairs we take part in every year. Read more about upcoming events .

About us

C-Trend™ technology is not available in the US.
"Finnish Cerenion has raised 500 000 euros in seed funding for its groundbreaking brain monitoring technology that holds great potential for improving intensive care…To date, the development of the technology and business has been funded by more than 1.1 million euros."
Good News from Finland
"Oulu’s ICT-focused enterprises are on track to raise a record amount of development capital in 2018, based on venture capital funding activity in January-February. Cerenion Oy is a case in point."
"Cerenion is a unique combination of deep research and a great complementary team that is creating a leader of a completely new category in healthcare. Their product will greatly help doctors in their work and save lives."
Riku Seppälä, Partner,
"The team is a great combination of different kinds of skills and expertise. Furthermore, they’re very execution focused and they have taken the case far already before the investment, both in terms of product as well as clinical validation. Superb team together with strong IP, clear market entry path and scalable business model are the ingredients that Cerenion is made of."
Juho Risku, Managing Partner, Butterfly Ventures
Visit us
Contact us
Cerenion Oy has received support from the European Regional Development Fund of the European Union.
Cerenion Oy
Elektroniikkatie 3
90590 Oulu
Cerenion Oy
Kyllikinportti 2
00240 Helsinki
Call us: +358 50 447 4909
E-mail us:
This website and all of the content therein is for reference purposes only and is not intended to substitute for advice from a licensed healthcare professional. Not available in the United States. Cerenion™, Cerenion C-Trend™, C-Trend™, "The next-generation brain monitoring company"™ and "The pulse of the brain"™ are registered trademarks and/or trademarks of Cerenion Oy. Cerenion C-Trend™ is intended for use by qualified medical practitioners who will exercise professional judgment in its use. Cerenion technology is protected by Intellectual Property Rights. Patents pending worldwide. All rights reserved. © Cerenion Oy 2020.
Powered by:MetaVisual CMSMobile versionDesktop versionLog in© 2017 - 2024 Cerenion Oy